Mesa Laboratories, Inc. (NASDAQ:MLAB) Stake Lessened by M&T Bank Corp

Posted by Defense World Staff on Sep 3rd, 2023

M&T Bank Corp lessened its stake in Mesa Laboratories, Inc. (NASDAQ:MLAB – Free Report) by 6.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,263 shares of the medical instruments supplier’s stock after selling 285 shares during the period. M&T Bank Corp owned about 0.08% of Mesa Laboratories worth $745,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Point72 Hong Kong Ltd acquired a new position in Mesa Laboratories in the first quarter worth $27,000. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main acquired a new position in Mesa Laboratories in the second quarter worth $41,000. Tower Research Capital LLC TRC boosted its holdings in Mesa Laboratories by 235.2% in the first quarter. Tower Research Capital LLC TRC now owns 295 shares of the medical instruments supplier’s stock worth $52,000 after purchasing an additional 207 shares during the period. Global Retirement Partners LLC boosted its holdings in Mesa Laboratories by 29.8% in the first quarter. Global Retirement Partners LLC now owns 414 shares of the medical instruments supplier’s stock worth $70,000 after purchasing an additional 95 shares during the period. Finally, Amundi acquired a new position in Mesa Laboratories in the fourth quarter worth $102,000. Institutional investors own 91.06% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com started coverage on shares of Mesa Laboratories in a report on Thursday, August 17th. They issued a “hold” rating for the company.

Check Out Our Latest Research Report on MLAB

Mesa Laboratories Stock Performance

Shares of MLAB opened at $140.43 on Friday. Mesa Laboratories, Inc. has a 1 year low of $114.21 and a 1 year high of $206.36. The company has a market cap of $756.08 million, a price-to-earnings ratio of 425.55 and a beta of 0.74. The company has a debt-to-equity ratio of 0.45, a quick ratio of 2.03 and a current ratio of 2.93. The firm has a fifty day moving average of $131.70 and a 200-day moving average of $150.48.

Mesa Laboratories (NASDAQ:MLAB – Get Free Report) last announced its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.13 by $0.09. Mesa Laboratories had a net margin of 0.83% and a return on equity of 9.36%. The company had revenue of $50.65 million during the quarter, compared to the consensus estimate of $51.85 million. As a group, equities analysts anticipate that Mesa Laboratories, Inc. will post 5.67 earnings per share for the current year.

Mesa Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 15th. Stockholders of record on Thursday, August 31st will be issued a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.46%. The ex-dividend date is Wednesday, August 30th. Mesa Laboratories’s dividend payout ratio (DPR) is 193.94%.

Mesa Laboratories Company Profile

(Free Report)

Mesa Laboratories, Inc develops, manufactures, and sells life sciences tools and quality control products and services in North America, Europe, the Asia Pacific, and internationally. It operates in four segments: Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions.